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The beta cells of the pancreas dynamically regulate insulin secretion, thereby maintaining blood glucose homeostasis. Destruction or dysfunction of these cells leads to type 1 and 
type 2 diabetes mellitus, a family of chronic diseases that currently 
affect over 415 million people worldwide1–3. Inadequate glucose 
control caused by loss of beta-cell function can lead to hyperglyce-
mia, a condition directly implicated in the development of severe 
complications, including blindness, renal failure and cardiovas-
cular disease4. However, the traditional intensive insulin therapy 
involving periodic injections imperfectly simulates the dynam-
ics of beta cells and can cause hypoglycemia, which is associated 
with risks of behavioral and cognitive disturbance, brain damage 
or death5–7. To this end, cell therapy is gathering momentum as 
a promising strategy for restoring tight glycemic control while 
mitigating episodes of both hyper- and hypoglycemia in patients 
with diabetes8–10. However, this approach is limited by a short-
age of donor islets and the requirement for immunosuppression 
after transplantation11.
As an alternative to the use of living cells for therapeutic purposes, 
a variety of biomimetic assemblies have been proposed to recreate 
the key functions of cells12,13. Prominent examples of complex assem-
blies include cell-membrane-cloaked nanoparticles, deformable 
microgels or vesicles bearing integrated proteins for detoxification, 
vaccination, hemostasis and drug release14–18. All such assemblies 
can be viewed as single-compartment structures, and their interac-
tions with biological entities are relatively passive compared with 
those exhibited by ‘living’ cells. Although multicompartmentalized 
assemblies have been created to reconstitute the hierarchical archi-
tecture of cells for delivering drug cocktails or conducting cascade 
reactions19–24, replicating the ‘sense-reactive’ behaviors of natural cells 
still remains elusive. Indeed, a key challenge in the de novo design of 
synthetic therapeutic cells is to mimic the higher-order functions of 
their natural counterparts that can precisely sense the external envi-
ronment, make internal decisions and trigger feedback12,25, processes 
routinely used by pancreatic beta cells in response to changes in gly-
cemic levels.
Like other biomolecule-secreting cells, beta cells export cellular 
cargos to the extracellular space through a vesicle transport sys-
tem and a membrane-fusion process after external stimulation26–28. 
To mimic this biochemical cascade, using a vesicles-in-vesicle 
superstructure as a rational starting point, we designed and engi-
neered a synthetic AβC (Fig. 1a and Supplementary Results, 
Supplementary Fig. 1). To our knowledge, this synthetic system is 
the first of its kind that can sense glucose levels and readily secrete 
insulin through vesicle-fusion-mediated behavior. The inner small 
liposomal vesicles (ISVs) are loaded with insulin to mimic the stor-
age granules inside mature beta cells, and the outer large vesicle 
(OLV) mimics the plasma membrane. To endow the system with the 
capability to both sense glycemic levels and release insulin via fusing 
ISVs with OLVs, the hierarchical liposomal assembly is equipped 
with a glucose-relevant metabolic system and pH-controllable 
membrane-fusion machinery. Glucose is taken up by the anchored 
glucose transporter 2 (GLUT2) and is subsequently oxidized into 
gluconic acid by glucose oxidase (Fig. 1a). The released protons rap-
idly decrease the pH in the system. The net pH variation is balanced 
by efflux through the proton channel gramicidin A inserted in the 
OLV membrane, which allows for greater variation in the internal 
pH levels under hyperglycemic conditions. Subsequently, the low 
pH associated with high glucose concentrations triggers dehybrid-
ization of the polyethylene glycol 5000–conjugated cytosine-rich 
DNA (PEG–CDNA) and the cholesterol-ended guanine-rich DNA 
(GDNA–CH) anchored on the ISVs, thereby sterically deshielding 
peptide K and making it available to form coiled coils with peptide 
E29–37 on the inner surface of the OLV. The two peptides’ ‘zipper-
ing up’ pulls the membranes of ISV and OLV tightly together and 
forces fusion, after which insulin is ‘exocytosed’. When the glucose 
concentration declines to a normoglycemic range, glucose uptake 
decreases, and the inner pH level increases, thus allowing the ISVs 
to reanchor with PEG–CDNA and subsequently inhibit the fusion 
event. In this biomimetic manner, the AβCs can effectively respond 
to hyperglycemia and resume their basal low level of insulin release 
under resting conditions.
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Generating artificial pancreatic beta cells by using synthetic materials to mimic glucose-responsive insulin secretion in a robust 
manner holds promise for improving clinical outcomes in people with diabetes. Here, we describe the construction of artificial 
beta cells (AbCs) with a multicompartmental ‘vesicles-in-vesicle’ superstructure equipped with a glucose-metabolism system 
and membrane-fusion machinery. Through a sequential cascade of glucose uptake, enzymatic oxidation and proton efflux, the 
AbCs can effectively distinguish between high and normal glucose levels. Under hyperglycemic conditions, high glucose uptake 
and oxidation generate a low pH (<5.6), which then induces steric deshielding of peptides tethered to the insulin-loaded inner 
small liposomal vesicles. The peptides on the small vesicles then form coiled coils with the complementary peptides anchored 
on the inner surfaces of large vesicles, thus bringing the membranes of the inner and outer vesicles together and triggering their 
fusion and insulin ‘exocytosis’. 
reSUlTS
Construction of the AbCs
To implement the AβC design, insulin-loaded ISVs were first pre-
pared via the classic lipid-film hydration method38, in which 4 mol% 
PEG–CDNA/GDNA–CH (Supplementary Fig. 2) and 1 mol% 
peptide K were inserted into the membrane by in situ modification. 
Transmission electron microscopy (TEM) images indicated an aver-
age ISV diameter of 50 nm (Fig. 1b). Because of the conformational 
switch between double-stranded duplex DNA and intramolecular 
tetraplex structures at physiological pH and acidic pH39,40 (pH <6.0; 
Supplementary Fig. 3), the PEG shield was able to reversibly attach 
to and disassociate from the ISVs, as evidenced by fluorescence 
resonance energy transfer (FRET) analysis (Supplementary Fig. 
4). The peptide K and peptide E were each designed with three fea-
tures: a transmembrane domain, a spacer and a recognition motif 
(Supplementary Fig. 5a), thus mimicking the SNARE membrane-
fusion proteins29–37. As such, heterodimeric coiled coils driven 
by the electrostatic and hydrophobic interactions of the heptad 
repeats in the recognition region formed when peptide E and pep-
tide K were mixed (Supplementary Fig. 5b). After insertion of the 
pH-responsive PEG shield in ISVs, an interaction between peptide 
E and peptide K was expected only in the unshielded state, on the 
basis of previous studies33,34. ISVs and glucose oxidase/catalase were 
encapsulated into OLVs decorated with 2 mol% peptide K by heat-
ing of interdigitated dipalmitoylphosphatidylcholine sheets above 
the gel–liquid phase-transition temperature41 (Supplementary Fig. 
6). Annealing of the interdigitated phospholipid sheets led to the 
formation of closed compartments with large size and high inter-
nal volume41, thus simultaneously entrapping enzymes and ISVs. 
Catalase was added to decompose the undesired hydrogen perox-
ide and regenerate oxygen, thereby facilitating glucose oxidation 
(Supplementary Fig. 7). The resulting vesicles-in-vesicle super-
structures with an overall size of ~1–5 μm were clearly observed in 
cryogenic scanning electron microscopy (cryo-SEM) images (Fig. 
1c,d), cryogenic TEM images (Supplementary Fig. 8) and confocal 
microscopy video (Supplementary Video 1). The localization of glu-
cose oxidase/catalase inside the cavities of OLVs was demonstrated 
by confocal laser microscopy imaging (CLSM; Fig. 1e). Next, GLUT2 
(details of expression and purification in Supplementary Fig. 9a and 
Supplementary Note) was reconstituted into the OLV membrane 
through a freeze–thaw sonication method. The presence of GLUT2 
on the OLV membrane was verified by western blotting (Fig. 1f; 
uncropped gel image in Supplementary Fig. 9b) and CLSM imag-
ing (Fig. 1g). Finally, gramicidin A, a membrane-spanning channel 
capable of conducting protons at very high flux rates42, was inserted 
into the OLV membrane, as shown in the CLSM image, by incorpo-
ration of lysine-5-carboxyfluorescein-ended gramicidin (Fig. 1h).
biochemical processes inside AbCs 
To determine the glucose-sensing ability of the AβCs, we coupled 
the glucose-transport machinery to an interior enzymatic-oxidation 
scheme and a pH-sensitive dye (Supplementary Fig. 10). The 
biochemical process was monitored through fluorescence mea-
surements (Fig. 2a,b and Supplementary Fig. 11a,b). At a fixed 
lipid/glucose transporter/glucose oxidase ratio, the inner pH level 
was dependent on the external glucose concentration as well as 
the amount of added gramicidin. At the same gramicidin level, the 
pH decrease was substantially faster at 400 mg/dL glucose (a level 
typical of hyperglycemia) than that at 100 mg/dL (a normoglycemic 
level). Moreover, similar pH variations but relatively slower kinet-
ics were observed at levels reflecting modest hyperglycemia (300 
and 200 mg/dL). The responsibility of the glucose transporter for 
glucose uptake was confirmed in control systems with no glucose 
transporter present as well as in the presence of the glucose-trans-
port inhibitor cytochalasin B (Supplementary Fig. 12). Given that 
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Figure 1 | Design and synthesis of AbCs. (a) Schematic of the biochemical processes inside the AβCs. GOx, glucose oxidase; CAT, catalase; square 
brackets denote concentration. (b) Top, ISVs stained with uranyl acetate and imaged by TEM. The ISVs were used to mimic the insulin granules inside 
natural beta cells (scale bar, 100 nm). Bottom, size-distribution histogram of the insulin-containing ISVs. (c) Top, cryo-SEM micrograph of the vesicles- 
in-vesicle superstructures (scale bar, 5 μm). Bottom, size distribution of vesicles-in-vesicle superstructures (ISVs@OLV). (d) Magnified fractured cryo-
SEM micrograph of the vesicles-in-vesicle superstructures (scale bar, 200 nm). From the fracture in d, small liposomal vesicles can be clearly seen inside 
the large liposome. (e) CLSM micrographs verifying the encapsulation of glucose oxidase labeled with fluorescein isothiocyanate (GOx-FITC) and catalase 
labeled with rhodamine B (CAT-RB) inside the large liposomes (scale bar, 5 μm). (f) Western blotting results indicating the retention of immunoreactivity 
of GLUT2 in the superstructures. The full gel is shown in Supplementary Figure 9. (g) CLSM image showing the reconstitution of GLUT2 labeled with 
rhodamine B on the membranes of the larger liposomes (scale bar, 5 μm). (h) CLSM image showing insertion of the proton channel gramicidin A labeled 
with lysine-5-carboxyfluorescein into the outer membrane (scale bar, 5 μm). 
oxidase has a Km of approximately 33–100 mM, the difference in 
the pH decline may be attributed to the different glucose-transport 
rates associated with high and low glucose concentrations. When 
the glucose concentration was held constant, the inner pH was 
inversely correlated with the gramicidin content: as more gramicidin 
was inserted, protons were pumped out of the AβCs more rapidly. 
In control systems in which no gramicidin was inserted, the final 
pH at 100 mg/mL was similar to that under hyperglycemic condi-
tions, although the pH decreased more slowly at 100 mg/dL thus 
indicating the necessity of gramicidin for tuning proton efflux 
to distinguish high and low glucose concentrations. The maxi-
mum pH change therefore relied on the overall kinetics of glucose 
uptake, glucose oxidation and proton efflux. For the following stud-
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Figure 2 | biochemical processes inside AbCs. (a–c) Glucose-sensing ability of AβCs. pH variation inside AβCs in 400 mg/dL (a) and 100 mg/dL  
(b) glucose solutions. The ratios represent the relative amount of gramicidin A to that of dipalmitoylphosphatidylcholine lipid. (c) Reversible pH variation 
induced by alternatively switching environmental glucose concentrations. (d–i) Signal transduction inside AβCs to control PEG deshielding and peptide 
assembly. (d) Schematic for reversible PEG association and disassociation tuned by glucose metabolism. PEG–CDNA was labeled with the DNA donor 
tetramethylrhodamine (pink), and GDNA–CH was labeled with the DNA acceptor IAbRQ (black). (e) FRET assay showing dehybridization of the pH-sensitive 
DNA duplex that bridges the PEG shield and the ISV surface at different glucose concentrations. (f) Reversible quenching and recovery of the fluorescence 
of the DNA donor, demonstrating the reversible attachment and detachment of the PEG shield in high and low glucose solutions. (g) Schematic illustration
of the quenching of the peptide donor nitrobenzofuran (blue) on peptide K by the peptide acceptor tetramethylrhodamine (red) on peptide E induced by 
peptide assembly after PEG dissociation. (h) FRET assay showing the interactions between peptide E and peptide K at different glucose concentrations. In 
e and h, F0 and Ft represent the fluorescence intensity (in arbitrary units (a.u.)) measured before and at time t after addition into glucose solutions. In inset,
I and II show the fluorescence spectra of the AβCs before and after incubation, respectively, in 400 mg/dL glucose solution. (i) Stepwise decrease in the 
fluorescence intensity of the peptide donor after alternation of the glucose concentrations. Error bars, s.d. of three independent experiments (n = 3).
maintained pH <5.6 under hyperglycemic conditions and pH >6.5 
under normoglycemic conditions. In this system, the pH inside the 
AβC switched in response to adjustments in glucose concentration 
(Fig. 2c and Supplementary Fig. 11c,d). Notably, the fast response 
in pH switching occurred because the diffusion of intermediates 
was minimized because all the biochemical processes were confined 
in a micrometer-scale space44. These unique properties enabled this 
artificial system to act similarly to natural beta cells in terms of pre-
cisely sensing graded glucose levels.
Next, we studied the ‘signal transduction’ inside AβCs, including 
the steric PEG deshielding and the subsequent peptide E–peptide K 
assembly. The disassociation of the PEG shield induced by glucose 
metabolism was confirmed via a FRET assay (Fig. 2d). The emis-
sion at 590 nm of the DNA donor tetramethylrhodamine on PEG–
CDNA, which was initially quenched by the DNA acceptor IAbRQ 
on GDNA–CH gradually increased in 200–400 mg/dL glucose 
solutions, whereas almost no change was observed in 100 mg/dL 
glucose solution (Fig. 2e and Supplementary Fig. 13a). Owing to 
the slow kinetics for pH variation at glucose levels corresponding to 
modest hyperglycemia, the changes in PEG deshielding took a rela-
tively longer time to initiate in 200 mg/dL and 300 mg/dL glucose 
solutions. A control study of a pair of randomly sequenced comple-
mentary DNA strands generated no fluorescence recovery at either 
high or low concentrations over time (Supplementary Fig. 14). 
Furthermore, reversible association and disassociation of the PEG–
CDNA was observed when the glucose concentrations were cycli-
cally varied between high glucose levels and 100 mg/dL (Fig. 2f and 
Supplementary Fig. 13b,c), thus indicating that the conformational 
conversion at high glucose levels induced duplex dehybridization 
and hence detachment of the PEG shield.
Next, expecting that the signals of other peptides or proteins 
would preclude the use of CD techniques, we used FRET to study 
the pairing of peptide K on ISVs with peptide E on OLVs (Fig. 2g). 
The fluorescence of nitrobenzofuran on the peptide donor peptide 
K was readily quenched by the peptide acceptor tetramethylrho-
damine on peptide E under high glucose concentrations (Fig. 2h 
and Supplementary Fig. 15a), and a stepwise decrease in peptide-
donor fluorescence was observed when the glucose concentration 
was alternated between high glucose levels and 100 mg/dL (Fig. 2i 
and Supplementary Fig. 15b,c). The lag at the beginning of each 
switch was due to the inner pH variation and the time required 
for the PEG-shield attachment/detachment to reach equilibrium; 
this lag was longer in glucose solutions reflecting modest hyper-
glycemia than after switching to the high glucose concentrations. 
Critically, no peptide interactions were detected at low glucose 
levels or in control groups in which non-pH-responsive DNA was 
used (Supplementary Fig. 16), indicating the direct dependence 
of peptide assembly on the dissociation of the PEG shield from 
ISVs, in which protons generated by glucose (signal) metabo-
lism act as the signal mediator, and the sequence-specific DNA 
strands act as the signal effector, thus allowing the signal trans-
duction inside AβC to induce PEG deshielding and subsequently 
activate peptide assembly.
membrane fusion of iSVs with olVs 
After a clear ‘signaling pathway’ was established, we next sought to 
substantiate the membrane fusion of the ISVs with OLVs which was 
driven by the interaction of peptide E and peptide K. By simulta-
neously incorporating lipids labeled with the lipid donor nitroben-
zofuran and the lipid acceptor lissamine rhodamine B into the 
ISV, we studied the efficiency of lipid mixing at different glucose 
concentrations, using a standard dequenching assay (Fig. 3a). At 
high glucose concentrations, a continuous increase in lipid-donor 
emission around 536 nm was observed, a result indicative of dilu-
tion of the lipid-donor and lipid-acceptor dyes induced by mem-
brane fusion (Fig. 3b and Supplementary Fig. 17a). In addition, 
as seen in the CLSM image (Fig. 3c), the green fluorescence of the 
lipid donor and the red fluorescence of the lipid acceptor gradu-
ally appeared and increased on the surfaces of AβCs in response 
to hyperglycemic conditions, and the fluorescence inside the 
AβCs gradually decreased, thus substantiating the merger of the 
ISV with the OLV. No obvious variations in lipid-donor fluores-
cence were observed under normoglycemic conditions (Fig. 3d). 
In further control experiments, no recovery in lipid-donor fluores-
cence was detected when either peptide E or peptide K was omit-
ted (Supplementary Fig. 18). Because peptide E and peptide K 
have been reported to be the minimal machinery that can mimic 
SNARE proteins for controlling membrane fusion31,32, these results 
therefore implied that peptide assembly tuned by glucose signal 
transduction brought the ISV and OLV close together and trans-
mitted the forces promoting their fusion.
In natural beta cells, vesicles can be trafficked to the periphery 
of the cell membrane with the assistance of the cytoskeleton45, thus 
leading to a sustainable fusion process. In the absence of machinery 
mimicking the cytoskeleton, ISVs moved randomly by Brownian 
motion within the AβCs, as shown in the CLSM images (Fig. 3c,d 
and Supplementary Video 1). Both the peptide assembly and the 
effective contact between the randomly diffused ISVs and the OLV 
contribute to the observed fusion processes within AβCs46, thus 
making the fusion process sustainable for several hours. In addi-
tion, cyclic switching of the glucose concentrations between hyper-
glycemic and normoglycemic levels resulted in stepwise increases 
in nitrobenzofuran fluorescence (Fig. 3e and Supplementary Fig. 
17b,c). Thus, on the basis of the glucose-sensing ability of AβCs 
and the reversible attachment of the PEG shield on ISVs, this new 
glucose-responsive mechanism promotes fusion under hyperglyce-
mic conditions and reshields the ISVs, thereby minimizing fusion 
under normoglycemic conditions for numerous cycles.
To exclude the possibility that the fusion process terminated at 
the stage of hemifusion30–32, we further studied whether the inner 
lipid layers of ISVs effectively mixed with the outer lipid layer of 
OLVs by bleaching the lipid-donor fluorophores on the outside of 
the ISVs with sodium dithionite (Supplementary Fig. 19a). An 
increase in lipid-donor fluorescence was detected at 400 mg/dL glu-
cose (Supplementary Fig. 19b). Because the FRET effect required 
the lipid-donor fluorophores inside the ISVs, complete merger of 
both the inner and outer lipid leaflets of the membranes of the ISVs 
and OLV occurred during fusion. Such full fusion of ISVs with 
OLVs is critical for the release of ISV cargoes outside the OLV in a 
manner that mimics cellular exocytosis.
In vitro dynamic insulin ‘secretion’ from AbCs 
In accumulated-insulin-release studies, a remarkably rapid insu-
lin release was detected at glucose levels reflecting hyperglycemia, 
whereas minimal release was observed at levels reflecting normo-
glycemia or in glucose-free buffer solution over 15 h (Fig. 4a and 
Supplementary Figs. 20 and 21a). Notably, the fast responsiveness of 
AβCs to 400 mg/dL glucose, as compared with the responsiveness of 
more conventional systems dependent on glucose oxidase–mediated 
pH decreases, resulted from the well-organized spatial confine-
ment of all relevant biochemical processes. This compartmental-
ization was similar to that in natural cells and also decreased the 
interference from the buffered environment11,47. Furthermore, the 
slower insulin release at modest glucose levels contributes to the 
dynamic response of AβCs toward different blood glucose lev-
els. When insulin was conjugated with fluorescein isothiocya-
nate, CLSM imaging showed more homogeneously distributed 
green fluorescence for AβCs in high-glucose solution, whereas 
clustered green signals remained in 100 mg/mL glucose after 
incubation for 6 h (Fig. 4b and Supplementary Fig. 21b), thus sub-
stantiating the release of insulin under hyperglycemic conditions. 
In control groups in which AβCs lacked either glucose-sensing 
machinery or membrane-fusion peptides, we observed slow and 
indistinguishable insulin-release kinetics at all glucose levels 
(Supplementary Fig. 22a,b). Furthermore, when the glucose con-
centrations were cyclically alternated between 400 mg/dL and 
100 mg/dL every 1 h for several repetitions, a pulsatile release profile 
was measured for AβCs, with a maximum eight-fold difference in 
insulin release (Fig. 4c). The low levels of released insulin detected 
after switching of the glucose concentration to normoglycemic 
levels was due to the lag across glucose metabolism, pH variation 
and membrane fusion. However, no such oscillations were found 
for the control AβCs (Supplementary Fig. 22c,d). In addition, no 
obvious insulin release was observed under mildly acidic pH levels 
(Supplementary Fig. 23), thus suggesting that nonspecific activa-
tion of AβCs would not occur in diabetic mice with diabetic ketoac-
idosis, which typically leads to plasma pH levels below 7.3 (ref. 48). 
These results illustrated that the oscillations in the glucose pathway 
and membrane fusion (demonstrated above) of AβCs effectively 
contributed to the oscillatory feature of insulin release, thus closely 
mimicking the dynamic secretion features of natural beta cells.
In vivo type 1 diabetes treatment 
We further tested the ability of AβCs to regulate blood glucose 
levels in vivo in a streptozotocin (STZ)-induced type 1 diabetic 
mouse model. Before in vivo studies, the retention of the secondary 
structure and the bioactivity of the insulin released from AβCs was 
verified (Supplementary Figs. 24 and 25). The AβCs were ‘trans-
planted’ into subcutaneous tissues by injection of a Pluronic F-127 
(PF127) solution (40 wt%) containing homogeneously distributed 
AβCs, a delivery method relying on PF127’s biodegradability and 
ability to quickly form a stable hydrogel at body temperature49 
(Supplementary Fig. 26). The distribution and integrity of AβCs 
inside the hydrogel were clearly observed under cryo-SEM imaging 
(Supplementary Fig. 27). In control groups, AβCs lacking insulin 
(AβC(no insulin)), lacking membrane-fusion peptides (AβC(no PE/PK)) 
or lacking glucose-sensing machinery (AβC(no GSM)) were also 
injected. The blood glucose in the mice treated with AβCs quickly 
declined from hyperglycemic to normoglycemic levels within 1 h, 
and subsequently the blood glucose levels remained normoglycemic 
for up to 5 d (Fig. 4d,e). In contrast, mice treated with AβC(no insulin) 
showed elevated blood glucose levels, thus excluding the possibility 
of a decrease in blood glucose levels induced by catalytic consump-
tion. For groups treated with control AβCs, elevated blood glu-
cose levels were also observed because of the lack of self-regulated 
glucose-sensing or membrane-fusion abilities. Correspondingly, 
plasma insulin levels in mice treated with AβCs remained detect-






























































































































































Figure 3 | membrane fusion of iSVs and olVs after glucose metabolism. (a) Fluorescence spectra of AβCs after incubation in 400 mg/dL glucose 
solution for the indicated times. The ISVs were simultaneously labeled with lipid donor (NBD, emission λmax = 536 nm) and lipid acceptor (LR, emission 
λmax = 592 nm). The total lipid-donor fluorescence spectrum was obtained by disruption of AβCs with 1% Triton X-100. (b) Kinetics profiles of lipid mixing 
between lipid-donor- and lipid-acceptor-labeled ISVs and OLVs in 400 mg/dL and 100 mg/dl glucose solutions, as indicated by the increase in lipid-donor 
emission. Each data point represents an average of triplicate measurements with standard error <10%. (c,d) CLSM images showing lipid mixing between 
lipid-donor- and lipid-acceptor-labeled ISVs and OLVs in 400 mg/dL (c) and 100 mg/dL (d) glucose solutions after different incubation times (scale bars, 
1 μm). The profiles show the distribution of the fluorescence intensity of lipid donor (green lines) and lipid acceptor (red lines) along the indicated white 
dashed lines. (e) Stepwise increase in the fluorescence of lipid donor after alternation of the glucose concentrations between 400 and  
100 mg/dL. Error bars, s.d. of three independent experiments.
detected in the plasma of control mice (Fig. 4f). Intraperitoneal 
glucose tolerance tests were performed to further test the in vivo 
glucose-responsive ability of AβCs at 24, 36 and 48 h after ‘trans-
plantation’ (Fig. 4g). At each time point, after showing a spike in 
blood glucose levels, mice that had received AβCs showed restora-
tion of prechallenge blood glucose levels at a rate comparable to that 
in healthy mice. Similar results were still observed on the fifth day 
after injection (Supplementary Fig. 28). However, this phenom-
enon was not observed for mice treated with control artificial cells 
in the same test (Supplementary Fig. 29). This in vivo responsive 
ability of the designed AβCs was further demonstrated by detec-
tion of the protein release in wild-type mice that were treated with 
AβCs loaded with human serum albumin 1.5 h after administration 
of glucose (Supplementary Fig. 30).
Importantly, AβCs(no insulin) were not associated with obvious cyto-
toxicity at any of the concentrations studied (Supplementary Fig. 
31). Finally, the injected formulation including PF127 was com-
pletely degraded by 4 weeks after administration, and no notice-
able inflammatory regions or fibrotic encapsulations were observed 
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Figure 4 | In vitro insulin secretion from AbCs and in vivo type 1 diabetes treatment. (a) In vitro accumulated-insulin release from AβCs incubated in 
solutions with different glucose concentrations. Data points represent mean ± s.d. (three independent experiments per group). (b) 2.5D CLSM images 
showing the fluorescence intensity and distribution of fluorescein labeled-insulin from AβCs before and after incubation in solutions containing different 
concentrations of glucose. (c) Pulsatile release profile by AβCs, showing the insulin release rate after alternation of the glucose concentration between 400 
and 100 mg/dL. Data points represent mean ± s.d. (n = 3). (d) Blood glucose levels of diabetic mice after treatment with AβCs or control AβCs lacking insulin 
(AβC(no insulin)), membrane-fusion peptide E and peptide K (AβC(no PE/PK)) or glucose-sensing machinery (AβC(no GSM)). Data points represent mean ± s.d. (n = 5 
mice per group). *P < 0.001 (analyzed by one-way ANOVA) for AβCs compared with control AβCs. (e) The blood glucose levels were continuously monitored 
in the first 12 h shown in d. Data points represent mean ± s.d. (n = 5 mice per group). (f) Variation in plasma insulin concentrations in diabetic mice over time 
after injection of AβC or control AβCs. Data points represent mean ± s.d. (n = 5 mice per group). (g) In vivo intraperitoneal glucose tolerance test (IPGTT) 
performed on diabetic mice at 24, 36 and 48 h after AβC treatment and on healthy control mice. Data points represent mean ± s.d. (n = 5 mice per group).
body-weight changes were observed between treated groups and 
the PBS-injected control group (Supplementary Fig. 33). In addi-
tion, the levels of inflammatory factors such as TNF, IL-1β and IL-6 
in the treated groups were similar to those in the control groups 
(Supplementary Fig. 34).
DiSCUSSioN
In conclusion, we demonstrated synthetic AβCs that recapitulate the 
key functions of beta cells, including sensing glucose levels, inter-
nally transducing signals and dynamically secreting insulin via ves-
icle fusion. Several differences exist between our AβCs and natural 
beta cells. The natural beta cells are electrically excitable and leverage 
variations in membrane potential, thereby coupling fluctuations in 
blood glucose levels to stimulation or inhibition of insulin secretion1. 
In contrast, the glucose sensing and stimulated insulin exocytosis 
inside AβCs are simplified into pH-tuned dynamic processes within 
confined microenvironments. Furthermore, natural beta cells secrete 
insulin via a biphasic process (involving a rapid first phase and pro-
longed second phase) that maintains a baseline level of insulin release 
at all times. In AβCs, the random collision of the insulin-containing 
ISVs with the outer membrane and subsequent induction of peptide 
interactions allowed a low level of the fusion process to be sustained 
for several hours. Moreover, the AβCs did not show the transient burst 
of insulin release that has often been reported in conventional pH-re-
sponsive materials, thus potentially conferring protection against life-
threatening insulin-induced hypoglycemia. Moreover, on the basis of 
the reversible nature of pH-tuned PEG attachment and detachment, 
pulsatile insulin release in response to graded glucose concentrations 
can run for many cycles, thereby potentially being able to withstand 
the blood glucose fluctuations that are prominent in even well-con-
trolled type 1 and type 2 diabetes. One of the greatest advantages of 
the AβCs is that they can be ‘transplanted’ directly within an inject-
able gel or potentially delivered through transcutaneous microneedle 
patches to restore blood glucose homeostasis2, thereby avoiding use 
of the immunosuppressive drugs required for transplantation of live 
cells. Our demonstration suggests that automated dynamic control 
of blood glucose concentrations to levels within a near-normal range 
would be feasible with synthetic artificial cells.
Nonetheless, opportunity exists in further improving the perfor-
mance of AβCs. For large-scale bioprocessing, the design and syn-
thesis of AβCs should be simplified without compromising the key 
functions mimicking natural beta cells. Another important aspect of 
the current design that needs improvement is the ability to provide 
continued insulin release for sustained therapy in a manner similar 
to that of natural beta cells or designer cells8,50; however, equipping 
synthetic cells with insulin- or other protein-replenishing machinery 
remains a major challenge. Moreover, issues regarding the accuracy 
of  ‘transplantation’ and the extent of the engrafted AβCs should be 
addressed to optimize the therapeutic performance. Although many 
gaps remain between biomimetic assemblies and natural cells, the 
described design principles lay a groundwork for developing next-
generation artificial cells with the goal of achieving long-term 
replacement therapy to correct for cell-function deficiencies51,52. 
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Methods, including statements of data availability and any associ-
ated accession codes and references, are available in the online ver-
sion of the paper.
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Materials and general methods. Materials. All lipids including egg phosphati-
dylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 
dipalmitoylphosphatidylcholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phospo-
ethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (ammonium salt) and 
1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine-lissamine–rhodamine 
B were purchased from Avanti Polar Lipids. All peptides were synthesized by 
Biochem Co. All DNAs were purchased from DNA Technologies. Cholesterol, 
glucose oxidase, catalase, gramicidin A, methoxypolyethylene glycol male-
imide (mPEG-Mal, MW 5,000), PMSF, n-dodecyl β-D-maltoside (DDM) 
and 8-hydroxypyrene-1, 3, 6-trisulphonic acid trisodium salt (HPTS) were  
purchased from Sigma-Aldrich. Human recombinant insulin was purchased 
from Life Technologies. Anti-GLUT2 antibody was purchased from Abcam 
(cat. no. ab54460).
Instrumentation. CD spectra were recorded with a Jasco J-815 spectropo-
larimeter while the sample cell was flushed with nitrogen. TEM images were 
acquired with a JEOL 2000FX scanning transmission electron microscope at 
200 kV. Fluorescence measurements were carried out with a FLS980 fluores-
cence spectrophotometer (Edinburgh Instruments). ELISAs, insulin detection 
and cell viability analysis were performed with an Infinite 200 PRO multimode 
plate reader (Tecan). Confocal microscopy images were obtained with a Zeiss 
LSM 710 confocal microscope (Carl Zeiss), and the samples were visualized 
with the same acquisition settings and analyzed in Zen 2011 software (Carl 
Zeiss). Confocal microscopy movies were recorded with a Zeiss LSM 880 
Airyscan microscope. Cryogenic TEM images were acquired with the help of 
the ICBR Electron Microscopy Core at the University of Florida. The blood 
glucose levels in mice were monitored with a Clarity GL2Plus glucose meter 
(Clarity Diagnostics). Cryo-SEM images were obtained with a JEOL 7600F 
microscope equipped with a Gatan Alto system. After cryofracture of the 
larger liposomes, the samples were then sublimated at −95 °C for 5 min under  
10−6-mbar vacuum. This step was used to reveal the internal fine structure by 
sublimating the ice crystals. The darker background outside the larger lipo-
somes was ice. From the differences in brightness, we were able to distinguish 
the ice and the small-liposome nanoparticles.
Statistical analysis. Biological replicates were used in all experiments. one-way 
analysis of variance (ANOVA) with Tukey post hoc tests was used to determine 
statistical significance between different groups. A P value <0.05 was consid-
ered to be statistically significant. All statistical analyses were performed in 
Origin 8.5. No statistical methods were used to predetermine the sample size of  
the experiments unless otherwise stated.
Design and synthesis of AβCs. Synthesis of PEG shield. 3′-thiolated cytosine-
rich DNA (CDNA) and mPEG-Mal solution at a DNA/mPEG-Mal molar ratio 
of 1:5 were mixed in HEPES buffer (1 mM, pH 7.5) and incubated for 4 h. The 
conjugation of PEG with CDNA was verified by agarose gel (1%) electrophore-
sis (Supplementary Fig. 2a), in which PEG–CDNA showed a much slower 
mobility than did CDNA. The cholesterol-ended guanine-rich DNA (GDNA–
CH) was then mixed with PEG–CDNA to form a duplex-DNA-bridged PEG 
shield (PEG–CDNA/GDNA–CH), which was inserted into liposome mem-
branes. The fluorescently labeled DNA and non-pH-responsive DNA-bridged 
PEG shield were prepared through the same process. The DNA-bridged PEG 
shields were lyophilized before preparation of liposomes. The sequences of all 
DNAs are shown in Supplementary Table 1. The conformational switch of the 
PEG–CDNA/GDNA–CH and non-pH-responsive DNA-bridged PEG shield at 
different pH values was studied by CD spectroscopy (Supplementary Fig. 3). 
From the CD spectra, no conformational variation was observed for the control 
DNA; however, for PEG–CDNA/GDNA–CH, the characteristic peak of DNA 
tetraplex at around 290 nm increased as the pH decreased. The CD spectra of 
PEG–CDNA/GDNA–CH indicated that the PEG–CDNA/GDNA–CH mainly 
existed as duplexes at and above pH 6.5, whereas the PEG–CDNA/GDNA–CH 
disassociated into tetraplexes at and below pH 5.5.
Preparation of insulin-loaded fusogenic ISVs labeled with peptide K and 
PEG shield. Lipid stock solution was prepared in chloroform with the com-
position of EPC/DOPE/CH 2.5:2.5:1 (w/w/w). Peptide K (50 μM) and PEG 
shield (50 μM) stock solutions were prepared in chloroform/methanol 1:1 
(v/v) and methanol, respectively. Then a solution of lipids, peptide K and 
PEG 
shield was prepared with a final molar ratio of 95:1:4 and added to a round-
bottom flask. Afterward, the solvent was evaporated with a rotary vacuum 
evaporator to yield lipid film, which was then dried under vacuum overnight. 
Next, insulin was dissolved in 4 mL HEPES buffer (5 mM and 150 mM NaCl, 
pH 7.4) and added to rehydrate the lipid film with gentle vortexing. A total of 
50 mg of insulin was used for each 100 mg of lipid. The resulting suspension 
was sonicated with a probe sonicator for 5 min with a power of 100 W and a 
time interval of 1s/1s to obtain a milky suspension. Afterward, the suspension 
was extruded ten times through polycarbonate membranes with a pore size of 
100 nm, by using an Avanti Mini Extruder. Free insulin was removed by cen-
trifugation at 20,000 r.p.m. for 60 min at 4 °C, and the liposomes were washed 
twice. To the sedimented liposomes, 4 mL HEPES buffer was added to yield 
the final insulin-loaded ISVs. The loading efficiency of insulin was calculated 
as the ratio of the concentrations of the liposome-associated insulin to the 
initially added insulin and was determined by a Coomassie Plus protein assay 
to be approximately 36.4%. ISVs without insulin or peptide K were prepared 
in the same manner and used in control experiments.
Preparation of interdigitated DPPC-bilayer sheets. To prepare interdigitated 
bilayer sheets41,53,54, DPPC dissolved in chloroform and peptide E dissolved 
in chloroform/methanol 1:1 (v/v) at a molar ratio of 98:2 were added to a 
round-bottom flask. After the solution was evaporated to form thin lipid films, 
HEPES buffer was added, and the film was hydrated at 60 °C. The final lipid 
concentration was 50 mg/mL. Afterward, the suspension was sonicated at 
60 °C for 5 min with a power of 100 W and a time interval of 1s/1s to obtain 
a milky suspension. Then the solution was extruded ten times sequentially 
through syringe filters with pore sizes of 200 and 100 nm at 60 °C to obtain 
liposomes with sizes less than 100 nm (Supplementary Fig. 6a,b). Afterward, 
interdigitated sheets were formed by dropwise addition of ethanol to 0.5 mL 
of the DPPC liposomes; the final concentration of ethanol was typically 3 M. 
The solution was allowed to sit for 2 h to ensure complete interdigitation. 
The resulting sheets were then washed three times through addition of 3 mL 
HEPES buffer to remove excess ethanol, subsequent centrifugation at 5,000 
r.p.m. and removal of supernatant. The obtained sheets were characterized by 
cryo-SEM (Supplementary Fig. 6c) and TEM (Supplementary Fig. 6d).
Building AßCs. To encapsulate ISVs inside OLVs, 0.5 mL of the ISVs prepared 
as above, 6 mg glucose oxidase and 1.5 mg catalase were added to one batch 
of the DPPC sheets prepared as above. Then the mixture was heated at 45 °C 
(above the main transition temperature of DPPC) for 20 min under gentle stir-
ring to drive the sheets to close around ISVs and glucose oxidase/catalase to 
form the vesicles-in-vesicle superstructures (ISVs@OLV)41,53,54. The free ISVs 
and glucose oxidase/catalase were removed by centrifugation at ~2,000 r.p.m. 
and were washed twice. All the supernatant was collected and ultracentrifuged 
to measure the loading efficiency of ISVs and glucose oxidase/catalase. The 
amount of ISVs encapsulated inside OLVs was determined indirectly on the 
basis of the amount of insulin in the free ISV. Approximately 52.8% of the 
ISVs were encapsulated. The unencapsulated glucose oxidase/catalase was 
detected by Bradford assays to measure the protein amounts in the supernatant 
after ultracentrifugation. Approximately 45.2% of glucose oxidase/catalase was 
encapsulated. Then GLUT2 (expression and purification methods described 
below) was reconstituted onto the OLV according to a previously reported 
method55. Approximately 1 mg of GLUT2 was mixed with one-fifth of the 
centrifuged ISVs@OLV in 0.5 mL HEPES buffer. After being mixed to homo-
geneity, the suspension in a tube was quickly frozen in liquid nitrogen for 
5 min and was subsequently sonicated for 20 or 30 s in a bath sonicator. The 
suspension was centrifuged at ~2,000 r.p.m. and washed twice to remove free 
GLUT2. The reconstitution efficiency of GLUT2 was determined to be 82% 
with GLUT2 ELISA kits. Finally, the proton channel gramicidin A in different 
ratios to DPPC in DMSO solution was added to the suspension of GLUT2-
recontituted ISVs@OLV used for the following experiments.
GLUT2 expression and purification. The cDNA encoding mouse GLUT2 
(Origene, GenBank NM_031197) was amplified and cloned into the BamHI and 
HindIII sites of pET-28a (Novagen; full plasmid sequence in Supplementary 
Note). The constructed plasmid was transfected into Escherichia coli Rosetta 
(DE3) pLysS cells for GLUT2 expression. The E. coli cells were cultured in 
lysogeny broth supplemented with kanamycin and chloromycetin, and pro-
tein expression was induced with 0.5 mM IPTG. The cells were collected by 
doi:10.1038/nchembio.2511
centrifugation and resuspended in buffer A (20 mM Tris-HCl, pH 8.0, 0.15 M 
NaCl, 10 mM imidazole, 1 mM PMSF, 5% glycerol, 0.4 mg/mL DNase I, 2% 
DDM and 0.5 mg/mL lysozyme). The suspension was incubated at 25 °C for 
0.5 h and kept on ice for another 0.5 h. After brief sonication, cell debris was 
removed by centrifugation (20,000g, 10 min). The clear supernatant was added 
to a column filled with Ni–NTA resin (Qiagen). After the column was washed 
with buffer B (20 mM Tris-HCl, pH 8.0, 25 mM imidazole, 5% glycerol, 0.15 M 
NaCl and 0.05% DDM), GLUT2 was eluted with buffer C (20 mM Tris-HCl, 
pH 8.0, 0.15 M NaCl, 500 mM imidazole, 5% glycerol and 0.05% DDM). The 
purified GLUT2 was quantified with Bradford assays (Bio-Rad), and the purity 
was analyzed through SDS–PAGE (Supplementary Fig. 9).
Biochemical processes inside AbCs. Glucose sensing and metabolism 
by AßCs. The fluorescence intensities of HPTS (514-nm emission; 406-nm 
(I406) and 460-nm (I460) excitation) were strongly dependent on the degree of 
ionization of the 8-hydroxyl group (pKa = 7.2) and hence on the pH of the 
medium. The I406 and I460 increased linearly with increasing HPTS concentra-
tion up to 2 μM (refs. 42,56). The titration curve of HPTS (0.5 μM) at different 
pH levels (5 mM HEPES buffer and 100 mM NaCl) was measured as shown 
in Supplementary Figure 10a. For glucose sensing, HPTS was loaded with 
ISV/GOx/CAT inside the OLV simultaneously during the encapsulation proc-
ess and was used as the pH probe to measure the pH variation inside AβCs, as 
induced by glucose uptake, glucose oxidation and proton efflux. To maintain a 
physiologically relevant and constant external glucose concentration, 100 μL 
HEPES buffer containing HPTS-loaded AβCs and glucose at different concen-
trations was added into the cup of a Slide-A-Lyzer MINI Dialysis Device (2K), 
and 1.5 mL isotonic solution containing the same concentration of glucose 
was added to the tube. The MINI Dialysis Device was then gently shaken at 
37 °C. At predetermined time intervals, 30 μL of the solution in the cup was 
removed, and the fluorescence intensities at 510 nm with 400-nm and 450-nm 
excitation were detected. The pH values inside AβC were calculated with the 
titration curve shown in Supplementary Figure 10b. After measurement, the 
solution was returned back to the cup of the MINI Dialysis Device. For the 
glucose-concentration-switching experiments, AβCs were first incubated in 
high-glucose solutions to reach equilibrium, and then AβCs’ ability to sense 
changes in glucose levels was assessed. After each switch, the inner pH was 
measured until equilibrium was reached, and then the AβCs were centrifuged 
and resuspended in another glucose solution. The cycles were repeated several 
times.
Signal transduction inside AßCs. We first studied the PEG-shield attachment 
onto and dissociation from the ISV surface, as triggered by the pH variation 
induced by glucose metabolism. Because our AβCs contained proteins or pep-
tides that also had CD signals, we alternatively applied the FRET method to 
monitor this process by using fluorescent dye (tetramethylrhodamine DNA 
donor) to label CDNA and quencher (IAbRQ DNA acceptor) to label GDNA 
(Supplementary Table 1). In these experiments, similarly to the glucose sens-
ing experiments, the AβC solution was collected at predetermined time inter-
vals or cycle runs, and the fluorescence variation of the DNA donor at different 
glucose concentrations was determined. To study the PEG-shedding-facilitated 
peptide assembly of peptide E on ISV with peptide K on the inner surfaces 
of OLVs, the FRET method was also used with lysine-nitrobenzofuran (pep-
tide donor)-modified peptide K and lysine-5-carboxytetramethylrhodamine 
(peptide acceptor)-labeled peptide E. The interaction of the peptide was deter-
mined on the basis of the quenching efficiency of the peptide donor by the 
peptide acceptor at different glucose concentrations.
Membrane fusion. The fusion of ISVs with OLVs in response to different glu-
cose concentrations was studied with a dequenching method based on FRET. 
Fluorescence experiments were carried out with ISVs colabeled with the FRET 
pair 1,2-dioleoyl-sn-glycero-3-phospoethanolamine-N-(7-nitro-2-1,3-benzox-
adiazol-4-yl) (ammonium salt) (lipid-donor, 0.5 mol%), and 1,2-dioleoyl-sn-
glycero-3-phosphatidylethanolamine-lissamine–rhodamine B (lipid acceptor, 
0.5 mol%). After incubation of AβC in different glucose solutions, the recovery 
of lipid-donor fluorescence was detected at different time intervals. The change 
in lipid-donor fluorescence intensity was plotted as: 
F F F F Ft(%) ( )/( )max= × − −100 0 0
where F0 is the lipid-donor fluorescence intensity at t = 0 before addition to 
glucose solution, Ft is the lipid-donor fluorescence intensity measured at time 
t, and Fmax is the lipid-donor fluorescence intensity after disruption of the AβC 
in 1% (w/v) Triton X-100.
In addition, the fusion process was monitored through confocal laser micro-
scopy imaging (Zeiss LSM 710). Images were obtained at different times after 
incubation in glucose solution.
For experiments demonstrating that no hemisfusion stage existed, the 
outer fluorescence of ISVs colabeled with lipid donor and lipid acceptor was 
bleached by incubation with sodium dithionate31 (Supplementary Fig. 19). 
The excess sodium dithionate was removed by centrifugation at 20,000 r.p.m. 
Then the fusion of the ISV inner membrane with the OSV outer membrane 
was detected through an identical dequenching assay.
In vitro dynamic insulin secretion from AβCs. 100 μL AβC mixed with glu-
cose solutions at different concentrations was added into the cup of a Slide-
A-Lyzer MINI Dialysis Device (2K), and 1.5 mL isotonic solution containing 
the same concentration of glucose was added to the tube. Then the MINI 
Dialysis Device was gently shaken at 37 °C. At the indicated time points, 
15 μL of the solution in the cup was removed and centrifuged at 6,000 r.p.m. for 
1 min. Then certain volumes of the supernatant were removed, and insulin was 
measured with a Coomassie Plus protein assay. The insulin concentration was 
calculated with a standard curve (Supplementary Fig. 21). For concentrated 
samples, dilution to the range of the standard curve was necessary. The remain-
ing mixture was adjusted to its previous volume with fresh glucose solution and 
re-added to the cup. For pulsatile release studies, the AβCs were first incubated 
within 400 ml/dL solution for 60 min and then spun down by centrifugation 
and washed once with HEPES buffer. The AβCs were then resuspended in 
100 mg/dL glucose solution for another 60 min. The cycles were repeated 
numerous times. Similarly, insulin concentration was determined with a 
Coomassie Plus protein assay.
In vivo diabetes treatment. Animals. Animal experiments were performed 
according to an animal protocol approved by the Institutional Animal Care 
and Use Committee at the University of North Carolina at Chapel Hill and 
North Carolina State University. STZ-induced C57BL/6 type 1 diabetic mice 
were purchased from the Jackson Laboratory. Experimental-group sizes were 
approved by the regulatory authorities for animal welfare after being defined 
to balance statistical power, feasibility and ethical aspects. For all the animal 
studies, mice were randomly allocated to each group. The researchers were 
not blinded to group allocation during the animal studies, as required by the 
experimental designs.
Diabetes treatment. The in vivo efficacy of AβCs was investigated in STZ-
induced adult diabetic mice (male, age 8 weeks). At 2 d before injection of 
the AβCs, the blood glucose levels of the mice were monitored with a Clarity 
GL2Plus glucose meter (Clarity Diagnostics) in ~3 μL blood collected from 
the tail vein, and all mice were fasted overnight before testing. To mimic beta-
cell transplantation, AβCs were suspended in 40% PF127 solution for ther-
mogel formation and subcutaneously injected into the dorsum in diabetic 
mice (Supplementary Fig. 26). A total of 300 μL of AβC/PF127 in PBS buffer 
or other control mixture was subcutaneously injected into the dorsum in mice 
given an insulin dose of 50 mg/kg after isoflurane anesthesia. Five mice in a 
stable hyperglycemic state were chosen from each group and subjected to 
administration of AβC(no insulin) or control AβCs that lacked either glucose-
sensing machinery or membrane-fusion peptides (AβC(no GSM) and AβC(no PE/PK)). 
The blood glucose levels of the mice were monitored over time (every 15 min 
or 1 h for the first 12 h after administration and once per day in the subsequent 
days) until stable hyperglycemia had been reached. To confirm the bioactiv-
ity of the released insulin, insulin solution (20 μg of native insulin or insulin 
released from AβCs at 400 mg/dL glucose for 6 h) was subcutaneously injected 
into the dorsum in diabetic mice. To measure the plasma insulin levels in vivo, 
25-μL blood samples were collected from the tail veins of mice at the indi-
cated time points. The plasma was isolated and stored at −20 °C until being 
assayed. The plasma insulin concentrations were measured with a Human 
Insulin ELISA kit according to the manufacturer’s protocol (Calbiotech). 
A series of glucose-tolerance tests were conducted at 24, 36 and 48 h after 
the injected materials and surrounding tissues were excised. The tissues were 
then fixed in 10% formalin, embedded in paraffin, cut into 5-μm sections and 
stained with hematoxylin and eosin for histological analysis. At that time, the 
body weights of the diabetic mice in each group were recorded. Moreover, 
for immunological analysis, representative inflammatory factors, such as 
TNF, IL-1β and IL-6, in the sera of mice from each group were measured by 
ELISA (eBioscience, Thermo Fisher Scientific) according to the manufacturer’s 
instructions.
Data availability. All data generated or analyzed during this study are included 
in this published article (and its supplementary information files) or are avail-
able from the authors upon reasonable request. A Life Sciences Reporting 
Summary for this paper is available.
treatment to confirm effective release of insulin from the AβCs in response to 
the glucose challenge. Briefly, glucose solution in PBS was intraperitoneally 
injected into all mice at a dose of 1 g kg−1. The blood glucose levels were closely 
monitored for 120 min after injection. Glucose tolerance tests on healthy mice 
were used as controls.
Cell culture. HeLa cells were obtained from the Tissue Culture Facility of 
the UNC Lineberger Comprehensive Cancer Center. The cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (Gibco, Invitrogen) with 10% (v/v) FBS 
(Invitrogen), 100 U ml−l penicillin (Invitrogen) and 100 mg ml−l streptomycin 
(Invitrogen) in an incubator (Thermo Scientific) at 37 °C under an atmosphere 
of 5% CO2 and 90% relative humidity. Cells were tested every three months 
for potential mycoplasma contamination. Reauthentication of cells was not 
performed after receipt.
Biocompatibility evaluation. The cytotoxicity of AβC(no insulin) was examined 
in HeLa cells through a 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetra-
zoliumromide (MTT) assay. Briefly, HeLa cells were seeded at a density of 
5,000 cells per well (200 μL total volume per well) in 96-well plates. After 
24 h, AβC(no insulin) at the indicated concentrations was added, and cells were 
further incubated for 24 h. Thiazolyl blue solution (5 mg mL−1) was added into 
the wells (final concentration 0.5 mg mL−1) and incubated with the cells for 
4 h. After removal of the culture medium, the purple formazan crystals were 
dissolved in 200 μL of DMSO. The absorbance at 570 nm, which is directly 
proportional to the viable cell number, was measured on an Infinite 200 PRO 
multimode plate reader (Tecan).
To evaluate the in vivo biocompatibility of AβC, 4 weeks after injection of 
AβC/PF127, the diabetic mice were euthanized via CO2 asphyxiation, and 
53. Boni, L.T. et al. Curvature dependent induction of the interdigitated gel phase 
in DPPC vesicles. Biochim. Biophys. Acta 1146, 247–257 (1993).
54. Ahl, P.L. et al. Interdigitation-fusion: a new method for producing lipid 
vesicles of high internal volume. Biochim. Biophys. Acta 1195, 237–244 
(1994).
55. Kasahara, M. & Hinkle, P.C. Reconstitution of D-glucose transport catalyzed 
by a protein fraction from human erythrocytes in sonicated liposomes. Proc. 
Natl. Acad. Sci. USA 73, 396–400 (1976).
56. Kano, K. & Fendler, J.H. Pyranine as a sensitive pH probe for liposome 
interiors and surfaces. pH gradients across phospholipid vesicles. Biochim. 
Biophys. Acta 509, 289–299 (1978).
Synthetic beta cells for fusion-mediated dynamic insulin secretion
Zhaowei Chen, Jinqiang Wang, Wujin Sun, Edikan Archibong, Anna R Kahkoska, Xudong Zhang, Yue Lu, Frances S Ligler, 
John B Buse & Zhen Gu
Nat. Chem. Biol.; doi:10.1038/nchembio.2511; published online 30 October 2017; corrected online 14 November 2017
In the version of this article initially published online, the wavelength depicted at the top of Figure 2g was mislabeled as 563 nm instead 
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